Cellect Biotechnology Ltd. (NASDAQ: APOP) is making a run for the top in the market this morning, and for good reason. The company announced clinical results, exciting investors and sending the stock running for the top. Today, we’ll talk about:
- The clinical results;
- what we’re seeing from APOP stock as a result; and
- what we’ll be watching for ahead.
APOP Climbs On Clinical Data
As mentioned above, Cellect Biotechnology is having an incredibly strong start to the trading session this morning after announcing positive clinical results. The results came by way of press release early this morning.
In the release, APOP provided the results from its collaboration with Cell2in. The company said that results of the third-party study further validate its Apograft™ technology. The results show a significant improvement in both proliferation and functional capabilities of hematopoietic and mesenchymal stem cells.
These stem cells originate from bone marrow, peripheral blood, umbilical cord, and adipose tissue. The technology is currently being developed with a goal of improving a variety of stem-cell based therapies.
In a statement, Shai Yarkoni, CEO at APOP, had the following to offer:
The data, which has now been validated through a third-party corporate collaboration, demonstrates that Cellect’s ApoGraft™ technology enables improved quality stem cell production at a lower cost by providing a platform technology aimed at benefiting multiple stem cell therapy products.
Together with our clinical data of allogeneic bone HSC (bone marrow) transplantation, this new program further supports the significance of the ApoGraft™ technology to all allogenic cell therapy. This is particularly relevant for MSCs, where the industry is moving towards off-the-shelf therapies requiring much larger expansions and represents a sizeable market opportunity for Cellect.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news causes moves. When it comes to Cellect Biotechnology, the news proved to be incredibly positive.
The strong data further validates the company’s work to improve the efficacy of stem-cell based therapy. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top.
As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:14), APOP is trading at $1.29 per share after a gain of $0.26 per share or 25.24% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on APOP. In particular, we’re interested in following the company’s continued work to further the development of its Apograft™ technology and provide value to shareholders. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!